Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Stock Short Interest Climbs 1,248.6%

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a significant growth in short interest in the month of October. As of October 30th, there was short interest totaling 56,588 shares, a growth of 1,248.6% from the October 15th total of 4,196 shares. Approximately 1.3% of the shares of the company are short sold. Based on an average daily volume of 67,008 shares, the days-to-cover ratio is currently 0.8 days.

Kiora Pharmaceuticals Price Performance

NASDAQ KPRX traded down $0.02 during trading hours on Thursday, reaching $1.33. 20,641 shares of the stock traded hands, compared to its average volume of 166,304. The company has a market cap of $5.88 million, a price-to-earnings ratio of -0.53 and a beta of -0.13. Kiora Pharmaceuticals has a 1 year low of $1.33 and a 1 year high of $2.91. The stock has a 50 day simple moving average of $2.33 and a two-hundred day simple moving average of $2.38.

Kiora Pharmaceuticals (NASDAQ:KPRX) last issued its earnings results on Thursday, November 12th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.38) by $0.10. The firm had revenue of $1.00 million during the quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Kiora Pharmaceuticals in a report on Monday, October 12th. One analyst has rated the stock with a Sell rating. Based on data from MarketBeat, the company presently has a consensus rating of “Sell”.

Institutional Investors Weigh In On Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. ADAR1 Capital Management LLC acquired a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 167,941 shares of the company’s stock, valued at approximately $442,000. ADAR1 Capital Management LLC owned about 3.80% of Kiora Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. Institutional investors and hedge funds own 76.97% of the company’s stock.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing therapies for diseases of the eye. The company’s research programs are aimed at addressing conditions with limited treatment options, including inherited retinal diseases and inflammatory eye disorders. Kiora’s lead program, KIO-301, is an investigational small-molecule therapy designed to function as a molecular photoswitch. The company is studying its potential to restore light perception in patients with vision loss caused by retinal degeneration, including retinitis pigmentosa.